Physician profile
Kevin Smith
NPI 1447463302
$985.65
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $144 · 2021: $137 · 2022: $14.90 · 2023: $29.64.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $29.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $29.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $173.73 | 2019-2021 | |
| Amgen INC. | $148.68 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $147.43 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.77 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $63.11 | 2019 | |
| Lilly USA, LLC | $59.90 | 2019-2020 | |
| Pfizer INC. | $57.50 | 2019 | |
| Glaxosmithkline, LLC. | $53.28 | 2019 | |
| Ironshore Pharmaceuticals INC. | $44.08 | 2019-2020 | |
| Abbvie INC. | $29.64 | 2023 | Qulipta, Ubrelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $21.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.90 | 2022 | |
| Amarin Pharma, INC. | $14.60 | 2020 | |
| Circassia INC. | $12.93 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $12.43 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $11.24 | 2019 | |
| Sunovion Pharmaceuticals INC. | $11.02 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.